Deutsch English Français

Contact

EP1831697

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1831697

EP1831697 - TUBULIN ISOTYPE SCREENING IN CANCER THERAPY USING HALICHONDRIN B ANALOGS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 23.12.2011 Database last updated on 30.09.2024
Most recent event Tooltip	23.12.2011	Application deemed to be withdrawn	published on 25.01.2012 [2012/04]
Applicant(s)	For all designated states Eisai R&D Management Co., Ltd. 6-10, Koishikawa 4-chome Bunkyo-ku Tokyo 112-8088 / JP
	[N/P]
Former [2008/28]	For all designated states Eisai R&D Management Co., Ltd. 6-10, Koishikawa 4-chome Bunkyo-ku Tokyo 112-8088 / JP
Former [2007/37]	For all designated states Eisai Co., Ltd. 6-10, Koishikawa 4-chome, Bunkyo-ku Tokyo 112-8088 / JP
Inventor(s)	01 / AGOULNIK, Sergei 62 Wildwood Road Andover, MA 01810 / US
	02 / KUZNETSOV, Galina 28 Wood Street Lexington, MA 02421 / US
	03 / LITTLEFIELD, Bruce, A. 4 Twinbrook Circle Andover, MA 01810 / US
	[2008/17]
Former [2007/37]	01 / AGOULNIK, Sergei 91 Marion Street Wilmington, MA 01887 / US
	02 / KUZNETSOV, Galina 28 Wood Street Lexington, MA 02421 / US
	03 / LITTLEFIELD, Bruce, A. 4 Twinbrook Circle Andover, MA 01810 / US
Representative(s)	Wallace, Sheila Jane, et al Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW / GB
	[N/P]
Former [2007/37]	Wallace, Sheila Jane, et al Lloyd Wise Commonwealth House, 1-19 New Oxford Street London WC1A 1LW / GB
Application number, filing date	05857058.1	07.12.2005
	[2007/37]
	WO2005US44421
Priority number, date	US20040634734P	09.12.2004 Original published format: US 634734 P
	[2007/37]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2006076100
	Date:	20.07.2006
	Language:	EN
	[2006/29]
	Type:	A2 Application without search report
	No.:	EP1831697
	Date:	12.09.2007
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 20.07.2006 takes the place of the publication of the European patent application.
	[2007/37]
Search report(s)	International search report - published on:	US	02.04.2009
	(Supplementary) European search report - dispatched on:	EP	30.12.2010
Classification	IPC:	G01N33/574	[2009/31]
	CPC:	A61K31/353 (EP,US); A61P35/00 (EP); G01N33/5091 (EP,US); G01N33/574 (EP,US); G01N33/57407 (EP,US); G01N33/57496 (EP,US); (+) G01N2500/00 (EP,US); Y10T436/143333 (EP,US) (-)
	Former IPC [2007/37]	G01N33/574, A61K31/353
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2007/37]
Extension states	AL	04.07.2007
	BA	04.07.2007
	HR	04.07.2007
	MK	04.07.2007
	YU	04.07.2007
Title	German:	SUCHE NACH TUBULINISOTYPEN BEI DER KREBSTHERAPIE UNTER VERWENDUNG VON HALICHONDRIN-B-ANALOGEN	[2007/37]
	English:	TUBULIN ISOTYPE SCREENING IN CANCER THERAPY USING HALICHONDRIN B ANALOGS	[2007/37]
	French:	CRIBLAGE DE L'ISOTYPE TUBULINE EN THERAPIE DU CANCER FAISANT APPEL AUX ANALOGUES DE L'HALICHONDRINE B	[2007/37]
Entry into regional phase	04.07.2007	National basic fee paid
	04.07.2007	Search fee paid
	04.07.2007	Designation fee(s) paid
	04.07.2007	Examination fee paid
Examination procedure	04.07.2007	Examination requested [2007/37]
	08.06.2009	Amendment by applicant (claims and/or description)
	29.07.2011	Application deemed to be withdrawn, date of legal effect [2012/04]
	09.09.2011	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2012/04]
Fees paid	Renewal fee
	24.12.2007	Renewal fee patent year 03
	24.12.2008	Renewal fee patent year 04
	28.12.2009	Renewal fee patent year 05
	27.12.2010	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]WO2004034990 (EISAI CO LTD [JP], et al) [X] 34-46,48 * claim 1 *;
		[X] - ZHANG ZHI-YI ET AL., "Characterization of in vitro metabolism of an anticancer agent E7389: Prediction of the potential risk of clinical drug-drug interactions.", DRUG METABOLISM REVIEWS, & 12TH NORTH AMERICAN ISSX MEETING; PROVIDENCE, RHODE ISLAND, USA; OCTOBER 12-16, 2003, (2003), vol. 35, no. Supplement 2, ISSN 0360-2532, page 184, XP009138348 [X] 34-48 * abstract *
		[X] - ZHENG W ET AL., "Macrocyclic ketone analogues of halichondrin B", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, GB, (20041115), vol. 14, no. 22, doi:10.1016/j.bmcl.2004.08.069, ISSN 0960-894X, pages 5551 - 5554, XP004598592 [X] 34-48 * table 1; compounds 4,9 * * page 5554, column l; table 1 * * Scheme 4 * DOI: http://dx.doi.org/10.1016/j.bmcl.2004.08.069
		[X] - TOWLE M J ET AL., "In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B", CANCER RESEARCH, US, http://cancerres.aacrjournals.org/content/61/3/1013.full.pdf, (20010201), vol. 61, no. 3, ISSN 0008-5472, pages 1013 - 1021, XP002335708 [X] 34-48 * figure 1; table 1 * * page 1020, column l, line 44 - column r, line 32 *
		[X] - ZHENG WANJUN ET AL., "Structure-activity relationships of synthetic halichondrin B analog E7389: In vitro susceptibility to PgP-mediated drug efflux.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, (200307), vol. 44, ISSN 0197-016X, page 540, XP001536720 [X] 34-46,48 * abstract *
	International search	[A]WO9965894 (EISAI CO LTD [JP], et al);
		[A] - KUZNETSOV G ET AL., CANCER RESEARCH, (2004), vol. 64, no. 16, pages 5760 - 5766, XP009128436 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-04-1169
		[A] - BAI ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, (1991), vol. 266, no. 24, pages 15882 - 15889, XP008119781
		[A] - KAVALLARIS M ET AL, CANCER RESEARCH, (2001), vol. 61, pages 5803 - 5809, XP008119782
		[P] - AGOULNIK ET AL, Journal of Clinical Oncology, 2005 ACSO Annual Meeting Proceedings., (20050601), vol. 23, page 16, XP008119836
		[P] - BLUM ET AL, Journal of Clinical Oncology. 2006 ASCO Annual Meeting Proceedings Part 1., (20060620), vol. 24, page 18

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p